Selected article for: "medical record and multivariate analysis"
Author: Lee, Hyun Woo; Yoon, Seo-Young; Lee, Jung-Kyu; Park, Tae Yeon; Kim, Deog Kyeom; Chung, Hee Soon; Heo, Eun Young
Title: Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients
  • Cord-id: pjvyy21l
  • Document date: 2020_12_1
    • ID: pjvyy21l
    Snippet: BACKGROUND/AIMS: Although a majority of coronavirus disease 2019 (COVID-19) cases were characterized as mild, data assessing the development of pneumonia in mild COVID-19 patients are limited. We aimed to examine the effect of pneumonia development on the clinical course of mild COVID-19 in hospitalized patients. METHODS: A retrospective cohort study was conducted via medical record review between February 25, 2020 and April 11, 2020 at a single center. The impact of pneumonia development on the
    Document: BACKGROUND/AIMS: Although a majority of coronavirus disease 2019 (COVID-19) cases were characterized as mild, data assessing the development of pneumonia in mild COVID-19 patients are limited. We aimed to examine the effect of pneumonia development on the clinical course of mild COVID-19 in hospitalized patients. METHODS: A retrospective cohort study was conducted via medical record review between February 25, 2020 and April 11, 2020 at a single center. The impact of pneumonia development on the time to viral clearance in mild COVID-19 patients was evaluated. Risk factors associated with the development of pneumonia were also identified. RESULTS: Chest radiographs revealed the development of pneumonia in 26.8% of mild COVID-19 patients. The time to pneumonia development was a median of 8.0 days from the onset of symptoms and 3.5 days after hospital admission. A multivariate analysis for predicting pneumonia development identified age ≥ 65 years (odds ratio [OR], 3.15; 95% confidence interval [CI], 1.14 to 8.73), cough (OR, 2.18; 95% CI, 1.29 to 3.68), dyspnea (OR, 3.58; 95% CI, 1.10 to 11.69), and diarrhea (OR, 2.69; 95% CI, 1.51 to 4.78) as significant variables. The time to negative conversion was longer in mild COVID-19 patients who developed pneumonia (23.6 days vs. 18.4 days, p = 0.003). In Kaplan–Meier estimation and multivariate Cox regression analyses, newly developed pneumonia was significantly related with delayed time to negative conversion (log-rank test, p = 0.02; hazard ratio, 2.90; 95% CI, 1.06 to 7.97). CONCLUSIONS: The development of pneumonia delayed viral clearance in patients with mild COVID-19. Elderly patients or those suffering from diarrhea should be closely monitored, given the increased risk of developing pneumonia.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest and acute respiratory distress syndrome respiratory failure: 1, 2
    • abnormal chest and admission fever: 1, 2, 3, 4
    • abnormal chest and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abnormal chest and logistic regression analysis: 1, 2, 3, 4
    • acute respiratory distress syndrome and admission date: 1, 2, 3
    • acute respiratory distress syndrome and admission fever: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome respiratory failure and admission fever: 1, 2
    • acute respiratory distress syndrome respiratory failure and logistic regression: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome respiratory failure and logistic regression analysis: 1
    • acute respiratory distress syndrome respiratory failure and lopinavir ritonavir: 1
    • adjust analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adjust analysis and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • admission date and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • admission date and logistic regression analysis: 1, 2, 3
    • admission date and lopinavir ritonavir: 1, 2, 3